A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)

NCT00497497 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: bevacizumab
DRUG: cetuximab
DRUG: FOLFIRI regimen
DRUG: irinotecan
DRUG: PRO95780

Sponsor

Genentech, Inc.